PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30344568-1	2018	Background & Objective: Large spectrum of pathogenic BRCA mutations is known as a major cause of hereditary breast ovarian cancer in human all over the world.	Adenosine Monophosphate	12-15	BRCA1 DNA repair associated	Homo sapiens	57-61	
15301716-1	2004	BACKGROUND & OBJECTIVE: The breast and ovarian cancer susceptibility gene BRCA1 acts as a tumor suppressor gene, its product expresses in a cell cycle-dependent manner.	Adenosine Monophosphate	12-15	BRCA1 DNA repair associated	Homo sapiens	78-83	
15142446-1	2004	BACKGROUND & OBJECTIVE: It is considered that tumor suppressor gene BRCA1 is an important factor in the regulation of cell cycle checkpoint, but the molecular mechanism by which BRCA1 regulates cell cycle G(2)/M arrest is less known.	Adenosine Monophosphate	12-15	BRCA1 DNA repair associated	Homo sapiens	72-77	
15142446-1	2004	BACKGROUND & OBJECTIVE: It is considered that tumor suppressor gene BRCA1 is an important factor in the regulation of cell cycle checkpoint, but the molecular mechanism by which BRCA1 regulates cell cycle G(2)/M arrest is less known.	Adenosine Monophosphate	12-15	BRCA1 DNA repair associated	Homo sapiens	182-187	
33339207-9	2020	Hence, [C16Pyr][Amp] was shown to be a promising anticancer therapeutic agent for BrCa and PCa cell lines.	Adenosine Monophosphate	16-19	BRCA1 DNA repair associated	Homo sapiens	82-86	
31897316-11	2019	Conclusion: The ACMG/AMP-based guidelines were applied to a cohort of patients with BRCA1 gene variants.	Adenosine Monophosphate	21-24	BRCA1 DNA repair associated	Homo sapiens	84-89	
25544836-1	2014	Myriad Genetics" long-time monopoly on BRCA gene testing was significantly narrowed by the Supreme Court"s decision in AMP v. Myriad Genetics, Inc., and will be further narrowed in the next few years as many of its still-valid patents expire.	Adenosine Monophosphate	119-122	BRCA1 DNA repair associated	Homo sapiens	39-43	
26784987-6	2016	In addition, one of the 9 active compounds, adenosine 5"-monophosphate (A5MP), and also its mimic 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) 5" phosphate (ZMP) inhibited RAD52 activity in vivo and exerted synthetic lethality against BRCA1 and BRCA2-mutated carcinomas.	Adenosine Monophosphate	72-76	BRCA1 DNA repair associated	Homo sapiens	244-249	
25238946-1	2015	Women with germline mutations in the cancer susceptibility genes, BRCA1 or BRCA2, associated with Hereditary Breast & Ovarian Cancer syndrome, have up to an 85% lifetime risk of breast cancer and up to a 46% lifetime risk of ovarian, tubal, and peritoneal cancers.	Adenosine Monophosphate	117-120	BRCA1 DNA repair associated	Homo sapiens	66-71	
24151232-0	2014	BRCA1-mediated inflammation and growth activated & inhibited transition mechanisms between no-tumor hepatitis/cirrhotic tissues and HCC.	Adenosine Monophosphate	50-53	BRCA1 DNA repair associated	Homo sapiens	0-5	
20038817-5	2009	Our results suggest that loss of BRCA1 function may contribute to the aggressiveness of Ras-MAPK driven human breast cancer with associated increase in levels of cyclin D1 and c-myc, enhanced MAPK activity, angiogenic potential & invasiveness.	Adenosine Monophosphate	229-232	BRCA1 DNA repair associated	Homo sapiens	33-38